Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Item

http://www.wikidata.org/entity/Q34579127

Q34579127

about

Activity of Sorafenib against desmoid tumor/deep fibromatosis Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments Trabectedin for advanced soft tissue sarcomas: optimizing use Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts New approaches for precise response evaluation in hepatocellular carcinoma Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin Current management and prognostic features for gastrointestinal stromal tumor (GIST)Imaging biomarker roadmap for cancer studies Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography.Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: Preliminary result.Selection for hepatic resection of colorectal liver metastases: expert consensus statement mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.Contrast-enhanced ultrasonography: advance and current status in abdominal imaging.Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study In vivo functional and anatomic imaging for assessment of in vivo gene transfer.Imaging beyond RECIST: CT and MRI in molecular therapies Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.Peripheral blood mononuclear CD133 mRNA levels correlates with response to treatment in patients with gastrointestinal stromal tumors Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.Systemic therapy options for unresectable and metastatic chordomas.The evolution of systemic therapy in sarcoma.Phase II study on lapatinib in advanced EGFR-positive chordoma.Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).

P2860

Q24620775-976E26A3-E8B0-436E-BAD4-114142492AE3 Q26738567-0CF32539-B4FC-4E2F-85A8-88955FF933D1 Q26783895-8EBE91D3-89A6-4A4D-854E-8AF29130F8FA Q26797292-BDF2C97B-C162-4F31-A91F-F66A20CDCB8F Q26852174-887F6B91-EE32-4837-BDF8-854417FB15B2 Q26860365-F5D20FF2-0A8D-4A44-AC5B-79817665F217 Q26863654-D5EB1D78-1806-424D-8CF5-79723C9C5DC3 Q26866367-96E85BD6-8C54-484C-96D8-485007D67CDD Q27009240-853952CE-F99B-42A0-97A9-773197387319 Q27027632-1CC70F36-7E80-42A6-A42C-C7604116F0BA Q27851995-7E765A6D-9F4A-402A-9869-E581D50B32A6 Q28069560-A85F52C1-D5A9-4269-9C77-76E79E3DC628 Q28074295-AFA74A49-A9B8-40E8-B56C-4857708A390C Q28087771-E8C5C74E-B6E0-4181-978D-5642240DA492 Q28391684-D2A796A1-C7E7-48DC-B44A-E0046ED81D47 Q30242020-31F0A4F7-69E1-4571-88F5-329BDCB22882 Q30365378-0D2EB21E-B104-4030-B4D0-17696287A060 Q30380915-90E847ED-7832-4E91-A9E9-76FF061D97BF Q30415026-4FF49212-8F40-4B9A-BB10-9171A37B2DD3 Q30415483-CA34FB06-7AA3-4C15-B9CE-0E7348893D62 Q30421027-77722CA2-46D4-4243-87D5-A72077AC8D74 Q30437854-D01FB8A2-B5B4-45F3-B4A1-E945F43BDA2C Q30460933-99728923-EE9C-46DF-A1D1-91048185FB3B Q30489867-35DABE70-2D9D-41D6-9713-8647CE974127 Q30571331-ED629C16-A4B6-4B1B-B5EA-461F754066DE Q30913383-4A045F52-010C-4107-8367-7BD0CE1E7786 Q31110927-D739F36B-8319-414C-AB43-D865254E3125 Q31112956-E56E1641-20F5-4322-A6E7-235B6823C98A Q33274146-7BDDF5AF-7848-40DA-A1C6-99B6DCAA136D Q33274710-2306652A-E525-45B5-B328-5C040C025371 Q33274760-0E2D6546-8E50-463D-89A9-D68AC4C327A6 Q33276227-5D5A49BF-7E09-4E83-98F1-7C5522E7FA22 Q33389519-8BB60A3A-D5AA-4808-8E62-77B7A438B999 Q33407600-E2F1AAC2-C40E-4635-A98E-67E0545CC3A5 Q33422577-F00A694B-BA6A-44B4-A5B5-8E84ED4EF096 Q33430940-60B22E68-00D6-4EFD-91EF-DBF280178BB1 Q33523445-47509DA8-4105-46A6-BE2A-F8B6DD4AB9EA Q33561602-47F28237-71A7-4CDA-B31D-8DF101DE86F1 Q33577856-82DBA31D-E0BF-41E9-A3E2-0EAB24C9818C Q33612778-958DC0CB-BC79-4482-8857-0A750E97FF2B

P2860

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Item

http://www.wikidata.org/entity/Q34579127

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu